Veralox is a clinical stage company developing first-in-class small molecule therapeutics that treat the underlying pathologies of immuno-inflammatory diseases heparin-induced thrombocytopenia (HIT) and type 1 diabetes (T1D), as well as several programs in the discovery phase.